Hepatitis C treatment response kinetics and impact of baseline predictors

Journal of Viral Hepatitis

Volumn 18, Issue 6, 2011, Pages 400-407

  Lindh, M ^a,j   Arnholm, B ^b   Eilard, A ^c   Farkkila M ^d   Hellstrand, K ^a   Lagging, M ^a   Langeland, N ^e   March, K ^e   Nilsson, S ^f   Pedersen, C ^g   Buhl, M R ^h   Wahlberg, T ⁱ   Wejstl, R ^a   Westin, J ^a   Norkrans, G ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Section of Hematology   (Sweden)

^c UDDEVALLA HOSPITAL   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h AARHUS UNIVERSITY   (Denmark)

ⁱ CENTRAL HOSPITAL   (Sweden)

^j Department of Virology ^*  (Sweden)

more..

Author keywords

genotype; HCV RNA; hepatitis; monitoring; pegylated interferon; ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; DISEASE SEVERITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS REPLICATION;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 79955365142     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01323.x     Document Type: Article

References (35)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965. (Pubitemid 32913521)
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
4. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001; 358 (9289): 1241-1242. (Pubitemid 33010853)
5. Dahari H, Ribeiro RM, Perelson AS,. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007; 46 (1): 16-21. (Pubitemid 47171916)
6. Jessner W, Stauber R, Hackl F, et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 2003; 10 (1): 37-42. (Pubitemid 36237810)
7. Layden JE, Layden TJ,. How can mathematics help us understand HCV? Gastroenterology 2001; 120 (6): 1546-1549. (Pubitemid 32322330)
8. Layden-Almer JE, Cotler SJ, Layden TJ,. Viral kinetics in the treatment of chronic hepatitis C. J Viral Hepat 2006; 13 (8): 499-504. (Pubitemid 44100400)
9. Lindh M, Alestig E, Arnholm B, et al. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol 2007; 45 (8): 2439-2445. (Pubitemid 47295471)
10. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282 (5386): 103-107. (Pubitemid 28471138)
11. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19 (3): 1-46.
12. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135 (2): 451-458.
13. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43 (5): 954-960. (Pubitemid 43724620)
14. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47 (1): 43-50. (Pubitemid 351171040)
15. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44 (1): 97-103. (Pubitemid 41772522)
16. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47 (1): 35-42. (Pubitemid 351171039)
17. Mangia A,. Short-duration therapy for hepatitis C: suitable for all? J Viral Hepat 2007; 14 (4): 221-227. (Pubitemid 46452415)
18. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129 (2): 522-527. (Pubitemid 41096640)
19. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357 (2): 124-134. (Pubitemid 47057730)
20. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47 (6): 1837-1845. (Pubitemid 351945551)
21. Pearlman BL, Ehleben C, Saifee S,. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46 (6): 1688-1694.
22. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131 (2): 451-460. (Pubitemid 44142452)
23. Berg T, von WagnerM, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130 (4): 1086-1097.
24. Batts KP, Ludwig J,. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19 (12): 1409-1417.
25. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 (6): 696-699.
26. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182 (1): 28-35. (Pubitemid 30497785)
27. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352 (25): 2609-2617. (Pubitemid 41007847)
28. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47 (6): 1884-1893.
29. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47 (10): 1260-1269.
30. Dahari H, Layden-Almer JE, Kallwitz E, et al. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology 2009; 136 (4): 1402-1409.
31. Yu ML, Chuang WL, Dai CY, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148 (3): 120-127.
32. Medeiros-Filho JE, de CarvalhoMelloIM, Pinho JR, et al. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J Gastroenterol 2006; 12 (45): 7271-7277. (Pubitemid 44911831)
33. Dahari H, Shudo E, Cotler SJ, Layden TJ, Perelson AS,. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther 2009; 14 (3): 459-464.
34. Basso M, Torre F, Grasso A, et al. Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. Dig Liver Dis 2007; 39 (1): 47-51. (Pubitemid 46024550)
35. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100 (11): 2453-2462.